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Surface plasmon field-enhanced fluorescence spectroscopy (SPFS) is a promising 
methodology for point-of-care (POC) testing. The SPFS devices which have been reported 
have been equipped with an angle rotating stage to adjust the surface plasmon resonance 
(SPR) angle. In a clinical setting, however, the SPR angle determination is a tedious and time 
consuming process. In this study, we employed an SPFS instrument with a convergent optical 
system that allows the omission of this procedure.  We demonstrated that this 
instrumentation allowed the sensitive determination of low concentrations of 
alpha-fetoprotein in serum and reduced the variation effect caused by the protein 
concentrations in samples. The SPFS with a convergent optical system is suitable for POC 
testing. 
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 Point-of-care (POC)1 testing allows medical personnel to carry out clinical tests at 
the bed side or near patients [1]. The results are immediately available, thus permitting the 
rapid application of clinical management decisions. Various methods such as paper 
chromatography [2], electrochemical analysis [3], surface plasmon resonance [4-7], and so on 
[8, 9] have been examined to develop point-of-care testing (POCT) devices. Surface plasmon 
field-enhanced fluorescence spectroscopy (SPFS) [10] (Scheme 1) is a promising method for 
the development of a highly sensitive POC device. SPFS utilizes a field-enhanced optical 
field of a surface plasmon mode for the excitation of fluorophores placed near the 
metal-dielectric interface. The evanescent field of a surface plasmon is enhanced by a factor 
of about 15 compared to the incident field for a gold-water interface at the specific resonance 
angle and then the signal decays exponentially into the dielectric medium, approximately Lz 
= 190 nm [11]. Thus, an SPFS-based sensor allows the sensitive determination of low 
concentrations of target molecules without the removal of unbounded complexes or B/F 
separation steps. Yu et al. reported a SPFS-based sensing device and achieved highly 
sensitive detection of free prostate specific antigen (f-PSA) [12]. Our group also developed 
an SPFS-based device and demonstrated quantitative detection of alpha-fetoprotein (AFP), a 
marker of hepatoma, at levels below the cut-off concentration for the clinical test [13]. Some 
problems, however, remain for the SPFS-based sensing devices used for POCT. Protein 
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concentration in patients’ blood varies within the range of 30-100 mg/mL [14, 15], resulting 
in large variation of its refractive indices. Conventional SPFS devices monitor a change in 
fluorescence intensity at a fixed incident angle near the surface plasmon resonance (SPR) 
angle, which is influenced by the refractive index near the metal-dielectric interface. 
Therefore, the incident angle must be carefully adjusted to be close to the SPR angle for each 
patient to maximize the field intensity of the surface plasmon and thus the fluorescence 
intensity.  
The SPFS-based devices, which have been previously reported, are equipped with an 
angle rotating stage to adjust the SPR angle [12, 13]. These devices should be small and 
consist of simple optical units for their application to POCT. In this study, we developed an 
SPFS-based device with a convergent optical system. Parallel incident light was focused 
through the lenses and a prism onto the back side of sensor chip surface, giving a fixed range 
of incident light angles. We examined the SPFS-based device with a convergent optical 
system for detecting AFP included in different concentrations of bovine serum albumin 
(BSA).  
 
Materials and methods 
Materials, reagents and antibodies 
11-Mercaptoundecanoic acid (Sigma-Aldrich Co., St. Louis, MO, USA), 
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1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC, Dojindo, Kumamoto, 
Japan), ethanol and N-hydroxysuccinimide (Nacalai Tesque, Kyoto Japan) and 
polyoxyethylene sorbitan monolaurate (Tween 20(R) equivalent, Wako Pure Chemical 
Industry, Osaka, Japan) were of reagent grade and used as obtained. Dulbecco’s PBS powder 
(D-PBS, Nissui Pharmaceuticals, Tokyo, Japan), bovine serum albumin (BSA, Sigma-Aldrich, 
USA), and alpha-fetoprotein (AFP, HyTest, Turku, Finland) were used as obtained. Fetal 
bovine serum (FBS, Biowest SAS, Nuaille, France) was heated at 56 °C to inactivate the 
complement system before use. Water was purified with a MilliQ system (Millipore Co.).  
Monoclonal mouse anti-human AFP antibody (clone 1D5 and 6D2) was obtained from 
Mikuri Immunological Laboratories (Osaka, Japan) and its solution was prepared and stored 
in accordance with supplier instructions. Anti-human AFP (clone 6D2) was labeled by 
fluorescence dye (Alexa-Fluor(R) 647) following the supplier’s instruction for the labeling 
kit (InvitrogenTM, Life Technologies, Co., Carlsbad, CA, USA.). Concentration of 
Alexa-Fluor 647 labeled anti-human AFP (clone 6D2) in the stock solution was determined 
by the method presented in the instruction from the absorbance at 280 nm and 650 nm and 
molar absorptivity (ɛAb=203,000) of antibodies. 
 
Preparation of SPFS apparatus with convergent optical system 
The SPFS apparatus with a convergent optical system (referred to as 
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SPFS-convergent) prepared in this study is schematically shown in Fig. 2(a). A 650 nm light 
source of pointed LED (BL15-1212, Kodenshi corp., Kyoto, Japan) was collimated using an 
aspheric optical lens (No.65989, Edmond Optics Japan, Ltd, Tokyo, Japan). The light was 
passed through an iris (IH-08R, Sigma Koki, Tokyo, Japan) to cut the light of which the 
directivity was larger than 5 degrees and then linearly p-polarized with an optical filter 
(NT47-215, Edmond Optics Japan, Ltd, Tokyo, Japan). An S-LAL10 glass plate coated with a 
chromium underlayer (1 nm) and a thin gold layer (49 nm) was optically coupled to a 
hemi-cylinder prism via immersion oil (ref. index: 1.720, Cargille Laboratories Inc., NJ, 
USA). A flow cell was assembled on the glass plate by fixing a poly(methylmethacrylate) 
(PMMA) plate through a spacer made of silicone rubber (thickness: 1 mm), and silicone 
tubes (inner diameter: 0.5 mm, outer diameter: 1 mm) were connected to the space on the 
glass plate through the PMMA plate [13]. The sample solution or D-PBS was delivered to the 
glass plate through the flow cell with a peristaltic pump (SMP-21, Tokyo Rikakikai Co., Ltd., 
Tokyo, Japan). The p-polarized and collimated light was focused on the gold layer by an 
aspheric optical lens (No.48164, Edmond Optics Japan, Ltd, Tokyo, Japan).  
The reflected light was captured by a CCD (ICX086AK; image sensor for NTSC 
color video cameras, Sony Corp., Japan) camera module (without cooling, outputting NTSC 
signals) and its image was recorded by a PC with recording software (VirtualDubMod ver. 
1.4.13.1jp2) and analyzed by ImageJ (ver.1.4.3). The fluorescence image on the surface of the 
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glass plate was collected through an objective lens (SLWD Plan20×, Nikon, Tokyo, Japan) 
and 670 nm interference filter (Optical Coatings Japan, Tokyo, Japan) with a high-sensitivity 
EM-CCD camera equipped with a charge multiplier (MC681-SPD; Texas Instruments, Dallas, 
TX, USA) cooled by a built-in peltier cooler. Acquired images were captured with an image 
capture board (MT-PCI2; Micro-Technica, Tokyo, Japan) and analyzed with home-made 
intensity scanning software. The fluorescence light intensities in selected areas (100 × 100 
pixels, corresponding to 210 µm × 210 µm) were determined. 
 
Preparation of SPFS apparatus with angle rotation stage 
The SPFS instrument of Kretschmann configuration was fabricated in-house 
(referred to as SPFS-1spot) [13], following the setup described by Knoll [10], with minor 
modifications. Briefly, a glass plate with a thin gold layer was coupled to a triangular prism 
via immersion oil (Cargille). A flow cell was prepared as mentioned above. A laser diode 
(Coherent, Santa Clara, CA, USA) was used as a source of incident light (λ = 635 nm, 0.95 
mW). The laser intensity was reduced to 10% with a neutral density (ND) filter. The laser 
was linearly p-polarized, then irradiated through a triangular prism at the back side of the 
glass plate. The incident angle was kept constant during fluorescence detection. The reflected 
light intensity was monitored with a photodiode detector (S2281-04; Hamamatsu Photonics, 
Hamamatsu, Japan). The fluorescence image on the surface of the glass plate was collected 
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by a CCD camera (MC681-SPD) and analyzed as mentioned above.  
 
Immobilization of antibodies on a sensor chip 
Glass plates (S-LAL10, refractive index: 1.720, 25×25×1 mm) were purchased from 
Sigma Koki (Tokyo, Japan). They were coated with a gold layer as previously reported [13, 
15]. Briefly, S-LAL10 glass plates were cleaned by plasma treatment in a plasma reactor 
(PA300AT; O-kuma Engineering Fukuoka, Japan) under 5 Pa O2 for 1 min., rinsed with 
deionized water and 2-propanol (Nacalai Tesque) three times each and then dried under a 
stream of nitrogen gas (Kyoto Teisan, Kyoto Japan). The glass plates were coated with 1 nm 
chromium and then with gold, 49 nm in thickness, by a thermal evaporation apparatus 
(V-KS200, Osaka Vacuum Ltd., Osaka, Japan). 11-Mercaptoundecanoic acid was dissolved in 
ethanol deoxygenized by bubbling of nitrogen gas. The gold-coated glass plate was immersed 
in a 1 mM solution of 11-mercaptoundecanoic acid at room temperature for at least 24 h to 
form a self-assembled monolayer (SAM) of the carboxy-terminated alkanethiol. Then, the 
glass plate was sequentially washed with ethanol and Milli-Q water three times each and then 
dried under a stream of dried nitrogen gas. A piece of silicone rubber sheet (Togawa Rubber 
Co., Ltd., Osaka, Japan) with a linear hole (6 x 15 mm hole) was placed onto the gold-coated 
glass plate carrying SAM. Carboxyl groups were activated using 0.1 mM 
ethyl-3-(3-dimethylaminopropyl)carbodiimide and 0.05 mM N-hydroxysuccinimide 
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dissolved in an aqueous D-PBS solutions for 15 min and rinsed with D-PBS two times. A 
solution of antibody of AFP (clone 1D5) was manually applied onto the linear hole and the 
coupling reaction was allowed to proceed at RT for 1 h. After the reaction, the surface was 
rinsed with D-PBS five times and then BSA solution (50 mg/mL in D-PBS) was applied for 
30 min to block free activated carboxyl groups.  Finally, the plates were rinsed with D-PBS 
seven times. The antibody-immobilized sensor chips were stored at 4 °C and used within a 
week. 
 
Refractive index measurement of solutions 
 Refractive indexes of D-PBS containing 30, 70, 100 mg/mL BSA were measured 
using an Abbe refractometer (DR-A1, Atago Co., Ltd., Tokyo, Japan) at 25 °C. 
 
Effect of BSA concentrations on SPFS-based immunoassay for detection of AFP 
 AFP solutions (5 ng/mL, 70 pM) in D-PBS with different BSA concentrations (30, 
70, 100 mg/mL) were prepared just before each experiment. Anti-human AFP 6D2 antibody 
labeled with Alexa-Fluor 647 (ahAFP-A647) was added to the AFP solutions at a final 
concentration of 10 nM and incubated at room temperature for 10 min to form an 
antibody-AFP complex. The antibody-AFP complex solution was applied to a sensor chip of 
the SPFS apparatus at a flow rate of 1 mL/min. Change of fluorescence intensity was 
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recorded in real-time by a highly sensitive CCD camera. The same sensor chip was 
repeatedly used in a series of experiments, that is, the sensor surface was washed by 10 mM 
glycine-HCl for 1 minute to remove antibody-AFP complex after each measurement and then 
antibody-AFP complex solutions containing different concentrations of BSA were applied. 
Obtained fluorescence intensities were normalized as ratios of the fluorescence intensity of 
the AFP solution containing 70 mg/mL BSA. 
 
Quantitative determination of AFP concentrations in fetal bovine serum 
 A series of AFP solutions (0–20 ng/mL) in FBS were prepared just before each 
measurement. An aqueous solution containing 35 mg/mL NaCl, whose refractive index is 
1.339, was applied onto a sensor chip to adjust the incident angle to the SPR angle. An 
ahAFP-A647 solution was added to 2 ml of AFP solution at a final concentration of 10 nM 
and incubated for 10 min to form the antigen-antibody complex at room temperature. The 
antigen-antibody complex in FBS was applied to a flow cell of the SPFS apparatus. 
Fluorescence intensity was recorded. New sensor chips were used in each measurement in a 
series of AFP solutions in FBS. 
 
Statistical analyses and detection limit 
Data from the experiments were expressed as the mean ± standard deviation (SD). 
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Detection limit was determined from the 3.3 SD of baseline measurements (FBS without 




Effects of protein concentration on the intensities of fluorescent light as detected by two SPFS 
devices with different optical units 
 Protein concentration in blood samples varies in patients from about 30 to 100 
mg/mL [14, 15]. Variations in refractive index due to changes in protein concentration would 
affect fluorescence intensity detected by SPFS devices. We employed 30, 70, 100 mg/mL of 
BSA solutions in D-PBS as a model for patient serums. Refractive indexes of 30, 70, 100 
mg/mL BSA solutions were 1.339, 1.346 and 1.351, respectively. Reflectance and 
enhancement factors of the evanescent field relative to the intensity of the incident light were 
calculated as a function of the incident angle using the Fresnel’s equation for the six-layer 
model (S-LAL10 glass/Cr/Au/SAM/protein adsorbed layer/protein solution) [18]. Fig. 1(a) 
shows dependences of reflectance and enhancement factors on light incident angles for the 30, 
70, 100 mg/mL BSA solutions. SPR angles, minimums of reflectance, and light incident 
angles which give maximums of enhancement factors are summarized in Table 1. The SPR 
angle and the light incident angle for maxima of enhancement factors increased with the 
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increase of BSA concentrations. Although there are small differences between the SPR angle 
and the angles which give the maximum of the field enhancement factor (Fig. 1(a)), this 
difference was ignored for SPFS in the following arguments. 
SPFS with convergent light beam: Fig. 2(a) shows the alignment of optical units. A 
parallel incident light beam was focused on the back side of the sensor of the SPFS apparatus. 
Incident angle range was set to be an angle that gave the maximum enhancement factor 
(θMEF) + 5.0° in the calculation for our SPFS optical unit. The fluorescent chromophore on 
the sensor surface was irradiated by the enhancement field developed by the incident light 
with a different incident angle, θMEF + 5.0°. Fluorescent intensity was expected to be 
proportional to the integration of enhancement field intensity within θMEF + 5.0°. When the 
center of the incident angle was fixed at the θMEF of 70 mg/mL BSA, i.e., 58.62°, the relative 
fluorescent intensities in BSA solutions of 30 and 100 mg/mL were calculated to be 99.9% 
and 99.8%, respectively, as compared to a solution of 70 mg/mL BSA. Therefore, the relative 
fluorescent intensity did not depend on protein concentrations.  
 SPFS with single light beam: Fig. 2(b) shows the alignment of optical units in an 
instrument with a single light beam. A light beam with small diameter is directed on the back 
side of the sensor of the SPFS apparatus. When this type of SPFS apparatus is used, an SPR 
sensory graph is first prepared by plotting the intensity of the reflected light against the 
incident light angle. Then, the incident angle of the light beam is carefully adjusted to a value 
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0.5° lower than the SPR angle [11] for each sample and then the fluorescent intensity is 
determined at that angle. In a clinical setting, however, this is a time consuming and tedious 
step. An SPFS apparatus with a fixed incident angle of the light beam should be employed. In 
the following calculation, the incident light is fixed at the angle which is optimal for 70 
mg/mL BSA solution, 58.62°. Changing the BSA concentration to 30 and 100 mg/mL led to 
slight decreases in the field enhancement factor of 93.3% and 94.7%, respectively, of that 
observed for a solution of 70 mg/mL BSA. Fluorescent light intensity is expected to be 
proportional to the intensity of the evanescent field. Therefore, this calculation indicates that 
the fluorescence intensity measured by the SPFS apparatus with single light beam is 
dependent on the protein concentration in the blood of patients.  
Fluorescent light intensities estimated for SPFS devices with different optical 
systems are also summarized in Table 1 for ease of comparison. These calculations indicated 
that the SPFS apparatus with convergent optical system efficiently suppressed the 
dependency of the fluorescence intensity on the protein concentrations in the serum in 
patients and thus is suitable for POC.  
 
SPFS apparatus with convergent optical system 
 Our SPFS apparatus with the convergent optical system was composed of an light 
source, alignment of optical units, SPR measurement and SPFS measurement units as 
13 
 
schematically shown in Fig. 2(a). A photograph of its prototype is shown in Fig. 3(a). Light 
from a pointed LED was passed through an iris, collimated, p-polarized, and then focused on 
the back side of a sensor, giving a fixed range (center ± 5º) of incident angle. Reflected light 
was captured by a CCD camera for SPR measurement and the fluorescence image on the 
sensor surface was observed by a highly sensitive CCD camera for SPFS measurement.  
An image of the reflected light is shown in Fig. 3(b-1) and a line profile of 
brightness is plotted as a function of pixel position in a horizontal direction, i.e., by varying 
the incident angle, in Fig. 3(b-2). Horizontal movement of the darker area reflects the change 
of the reflective index on the sensor surface. The SPR angle was determined from this line 
profile as a pixel position at which light intensity displayed the smallest value, as indicated by 
a dotted line. Fig. 3(c-1) also included an SPFS image obtained by a highly sensitive CCD 
camera during the flow of the AFP-antibody-fluorescent chromophore complex over a sensor 
chip functionalized with primary anti-AFP antibody. SPFS images were sectioned into 26 
small areas with 100 x 100 pixels. Integrated intensities of fluorescent light in each area were 
calculated with home-made analysis software and are plotted with time in Fig. 3(c-2). 
Averaged whole area fluorescent intensity was employed hereafter. 
 
Quantitative measurement of AFP in fetal bovine serum 
 The efficacy of our SPFS system for detection of low levels of AFP in serum was 
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evaluated by using solutions of AFP in FBS. Anti-human AFP 6D2 antibody labeled with 
Alexa-Fluor 647 was mixed with AFP solution in FBS and incubated at room temperature for 
10 min to form an AFP antibody-Alexa-Fluor 647 complex. The solution was applied to a 
sensor surface on which primary anti-AFP antibody was immobilized. The intensities of 
fluorescent light were integrated for 26 small areas (Fig. 3(c-1)) before and after the AFP 
antibody-Alexa-Fluor 647 complexes were applied. Fluorescent light intensity caused by the 
complex on the sensor surface was estimated by the difference between the integrated light 
intensity before and after the complex was applied. As shown Fig. 4(a), the fluorescent light 
intensity from the complex on the sensor surface linearly increased with time, indicating that 
the antibody-AFP complex was bound to the primary antibody immobilized on the sensor 
chip. Larger increments of fluorescence intensity were observed with increasing AFP 
concentrations. The elevations in the rates of fluorescence intensities were used to rapidly 
determine AFP concentration in solutions. The slopes of the lines, corresponding to changes 
in fluorescent intensity as a function of time, were plotted against the AFP concentrations 
(Fig. 4(b)). Linear regression analysis of these plots (Fig. 4(b)) indicated a strong linear 
relationship (R2 = 0.995). The standard derivation of the elevation in the rates of fluorescence 
intensity obtained from FBS without AFP was 338 a.u./min (n=12). Therefore the limit of 




 Effect of protein concentration on fluorescence intensity 
 As shown in Table 1, we previously examined the effect of protein concentration on 
fluorescence intensity in the SPFS apparatus with the convergent optical unit using Fresnel’s 
equation. The incident angle was adjusted to be optimal for detecting AFP in 70 mg/mL BSA.  
Mixtures of anti-human AFP antibody labeled with Alexa-Fluor 647 and 70 pM AFP in 
solutions containing 30, 70, or 100 mg/mL BSA were applied to the sensor surface. The 
fluorescent light intensity linearly increased with time (Fig. 5). The rates of the elevations of 
fluorescence intensity varied with BSA concentrations. Relative elevation rates for 30 and 
100 mg/mL BSA/DPBS solutions were 0.97 and 0.92, respectively, for the convergent light 
SPFS apparatus.  
 
Discussion 
We assessed the efficacy of our SPFS apparatus with a convergent optical system as 
a POC device with high sensitivity. Immunoassay of AFP using our SPFS apparatus 
demonstrated that the fluorescent intensity increased linearly due to binding of 
AFP-antibody-Alexa-Fluor 647 complex to a sensor surface and the slope was in proportion 
to the AFP concentrations (Fig. 4(b)). Our SPFS-based immunoassay could determine the 
AFP concentration within 20 min after we received the plasma sample. The limit of detection 
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for AFP in FBS was determined to be 0.68 ng/mL. There are several sensitive assay methods 
used in clinical diagnosis, such as enzyme-linked immunosorbent assays (ELISA), 
chemiluminescence immune assay (CLIA), and radioimmunoassay (RIA). The detection limit 
of AFP is about 2 ng/mL for commercially available ELISA [19], 0.5 ng/mL for ECLIA [20], 
and RIA [21]. Approximately 97% of the healthy subjects have AFP levels less than 8.5 
ng/mL [22]. We therefore concluded that our prototype SPFS apparatus is sensitive enough 
for clinical diagnosis of AFP concentrations and gives clinical test results within the 
permissive range of time for measurements at the bed-side. ELISA, CLIA, and RIA, all of 
which are clinically used, require more than 10 steps including washing samples to remove 
unbound complexes. In contrast, our SPFS-based immunoassay could determine AFP 
concentration in samples without removal of unbound complexes (Fig. 4). This result makes 
this SPFS apparatus suitable for POC testing, eliminating the time consuming and tedious 
procedures and allowing immediate clinical management decisions to be made. 
The application of this SPFS apparatus to clinical diagnosis will benefit from some 
improvements. The SPFS apparatus utilizes the enhanced evanescent field caused by the SPR 
phenomenon of excitation of a fluorescent dye. As shown in Fig. 1, the light incident angle, at 
which the evanescent field gives its maximum response, depends on the refractive index near 
the metal surface. Therefore, fluorescence intensity changed in a manner dependent on the 
protein concentration of the sample, even though the concentration of the antigen AFP 
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remained the same. We developed the SPFS apparatus with the convergent optical system to 
solve this problem and expected that the incident light angle would equal the SPR angle + 5°. 
Theoretical calculation using Fresnel’s equation and experiments demonstrated less variation 
in the changes in fluorescence intensity caused by differences in protein concentration. 
Although the SPFS-convergent apparatus greatly suppressed the effect of BSA concentration 
on the relative increases in the rates of fluorescence increase (Fig. 5), these dependences were 
larger than those calculated using Fresnel’s equation. We suspect non-uniformity of the 
incident light might be the cause of the difference between the experimental and calculated 
values. Ideally, the intensity of the incident light should be the same at any incident angle. A 
LED was used as a light source in our SPFS apparatus and the emitted light whose directivity 
was larger than 10° was cut by an iris to obtained uniform light flux. As seen in the SPFS 
image shown in Fig. 3(c-1), however, its central section was brighter than its periphery.  
Thus, the illumination assembly needs to be improved to reduce the size of illuminated area. 
Additionally, the use of a photomultiplier instead of CCD camera might improve readability 
of signal by permitting the collection all fluorescence light emitted from the sample. 
 Many bright spots were observed in SPFS image of the sensor surface as shown in 
Fig. 3(c-1). Their size was larger than 10 µm in diameter. When a gold surface was observed 
by an optical microscope and an atomic force microscope, such large granules were not found. 
These bright spots might be caused by coupling of surface plasmon-polaritons due to the 
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roughness of the granules of gold on a sensor chip, as pointed out by Rothenhaesler [23]. If 
number and location of these spots could be well controlled, fluorescent intensities would be 
greater enhanced due to the effect of localized plasmon-polaritons. These bright spots, 
however, caused heterogeneity of the sensor-chip surface, making difficult the direct 
correlation between fluorescent intensity and antigen AFP concentration.  
 
Conclusions 
 We fabricated an SPFS apparatus using a convergent optical system, giving a fixed 
range or incident light. Both theoretical calculation and immunoassay of AFP demonstrated 
that our SPFS apparatus was relatively robust against fluctuations of refractive indexes of 
specimens. This apparatus could determine concentrations of AFP in FBS quantitatively 
under the concentration of clinical cut-off of AFP. Our results will contribute to the 
development of small, simple but highly sensitive and precise measurement devices. 
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Figure captions  
 
Scheme 1. Schematic illustration of SPFS-based immunoassay for the detection of AFP. (a) 
The primary antibody was immobilized on the sensor surface; (b) AFP-antibody complex was 
flowed over the sensor surface; (c) The primary antibodies captured the AFP complexes and a 
fluorescence detector (CCD camera) captured fluorescent image used by the AFP complexes 
bound on the sensor surface. 
 
Fig 1. Calculation of reflectance and enhancement factors of the evanescent field relative to 
the intensity of the incident light as a function of the incident angle using the Fresnel’s 
equation for the six-layer model (S-LAL10 glass/Cr/Au/SAM/protein adsorbed layer/protein 
solution). The calculation was performed in the presence of BSA solutions with different 
concentrations: - - - - -; 30 mg/mL (refractive index, n = 1.3389), ―――; 70 mg/mL (n = 
1.3456),· · · · ·; 100 mg/mL (n = 1.3505). SPFS apparatus with a convergent light beam 
detects fluorescence at a fixed range of the incident angle (shaded area) while SPFS device 
with a single light beam detects fluorescence at a fixed incident angle (solid line). 
 
Fig. 2. Two kinds of SPFS devices. (a) SPFS device with a convergent light beam. The light 
was passed through an iris (IH-08R, Sigma Koki, Tokyo, Japan) to cut the light of which 
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directivity was larger than 5°, paralleled and then the parallel light was converged on the back 
side of the sensor. (b) SPFS device with a single light beam. A parallel single beam with 
small diameter is directly irradiated on the back side of the sensor. 
 
Fig. 3. SPFS device with a convergent light beam. (a) Photo of a prototype device; (b-1) CCD 
image of reflected light; (b-2) Line profile of the CCD image. (c-1) Fluorescent image 
obtained by the SPFS device with a convergent light beam during flowing of 
AFP-antibody-Alexa-Fluor 647 complex (AFP: 5 ng/mL). Yellow boxes indicate regions at 
which light intensity are measured. (c-2) Changes of fluorescence intensity at each region 
shown in panel c-1 during flowing of AFP-antibody-Alexa-Fluor 647 complex (AFP: 5 
ng/mL) over a sensor chip functionalized with primary anti-AFP antibody.  
 
Fig. 4. Detection of AFP by an SPFS device with a convergent light system. (a); Fluorescence 
intensity changes during the flow of FBS solutions containing ahAFP-A647-AFP with the 
indicated AFP concentrations over a sensor chip of a SPFS device with a convergent light 
system. Lines represent linear fittings of data points to calculated slopes of the increases in 
fluorescence intensity over time (R2 = 0.995). (b): Slopes of increases of fluorescence 
intensity as a function of time are plotted against AFP concentrations. Dot line shows means 
+ 3.3SD in the absence of AFP. 
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Fig. 5. Changes in fluorescence intensity during flowing of hAFP-A647-AFP complexes. 
AFP (5 ng/ml) in solution with different SPA concentrations detected by SPFS with a 




Table 1. Summary of theoretical calculations for immunoassay detected using SPFS 
apparatus with single light beam and with convergent optical system. 
 
 Bovine serum albumin concentration, mg/ml 
  30 70 100  
Refractive index  1.339 1.346 1.351  
SPR angle  58.68 59.15 59.51  
Angle gives maximum enhancement 
factor 
 
58.15 58.62 58.97 
 
Enhancement factor at the angle optimal 
for 70 mg/mL BSA 
     
SPFS with convergent light beam  5.730 5.736 5.726  
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